COVID-19 Vaccination Status and Side Effects in Ulcerative Colitis Patients

  • Straume, Z. (Speaker)
  • Nikola Krumina (Co-author)
  • Ilze Elbere (Co-author)
  • Maija Rozenberga (Co-author)
  • Juliana Ozolina (Co-author)
  • Krūmiņa, A. (Co-author)
  • Skuja, V. (Co-author)

Activity: Talk or presentation types › Poster presentation

Description

Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccination is recommended for all individuals with inflammatory bowel disease (IBD), including those on immunosuppressive therapies; however, little is known about vaccination status, frequency and side effects safety and efficacy in IBD disease course.. In 6-month time (June 2021 to December 2021) 49 ulcerative colitis (UC) outpatients from Riga East Clinical University Hospital were included in a Cross-sectional study. All patients were divided into groups according to medically proven data about COVID-19 status (COVID-19+ vs COVID-19-) in the last 6 months. Information about vaccination status and complaints after vaccination were collected. Data were analyzed with SPSS 20.0.. Out of 49 patients, 33 (63.3%) were males and 13 (36.7%) were females, mean age was 38.0 Md[Q1-Q3:34.0-51.0]. Most UC patients were vaccinated (23 (41%) males and 9(16%) females, p=0.000). The most common vaccine was: Comirnaty (19(33,9%)) and Spikevax (7(12,5%)). Twenty-four (49%) patients had side effects after vaccination. Nineteen (38.8%) had side effects after the first vaccine, 6 (12.2%) after the second vaccine, and one (2,04%) – after the third vaccine. The most common side effects were local hyperemia in 22 (16 (28.6%) males, 6(10,7%) females), subfebrile temperature in 7(12,5%) males, and bone pain in 4 patients (3(5,4%) males, one (1,8%) female). The worst side effect after the first vaccination was pancreatitis (in one case), after 3rd: the first onset of UC (in one case). There was no statistical significance between age, gender, and side effects after vaccination. Fourteen patients (28.6%, 7(50%) in each gender) have been Covid-19 positive.. Most UC patients received the COVID-19 vaccine. The most common vaccine used among UC patients were Comirnaty and Spikevax. Males were vaccinated more often than females. Almost half of UC patients had a side effect after vaccination.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content